Nature Communications (Feb 2021)
Efficacy and tolerability of bevacizumab in patients with severe Covid-19
- Jiaojiao Pang,
- Feng Xu,
- Gianmarco Aondio,
- Yu Li,
- Alberto Fumagalli,
- Ming Lu,
- Giuseppe Valmadre,
- Jie Wei,
- Yuan Bian,
- Margherita Canesi,
- Giovanni Damiani,
- Yuan Zhang,
- Dexin Yu,
- Jun Chen,
- Xiang Ji,
- Wenhai Sui,
- Bailu Wang,
- Shuo Wu,
- Attila Kovacs,
- Miriam Revera,
- Hao Wang,
- Xu Jing,
- Ying Zhang,
- Yuguo Chen,
- Yihai Cao
Affiliations
- Jiaojiao Pang
- Department of Emergency Medicine, Shandong Provincial Clinical Research Center for Emergency and Critical Care Medicine, Institute of Emergency and Critical Care Medicine of Shandong University, Qilu Hospital of Shandong University
- Feng Xu
- Department of Emergency Medicine, Shandong Provincial Clinical Research Center for Emergency and Critical Care Medicine, Institute of Emergency and Critical Care Medicine of Shandong University, Qilu Hospital of Shandong University
- Gianmarco Aondio
- Department of Medicine and Oncology, Moriggia-Pelascini Hospital, Gravedona ed Uniti
- Yu Li
- Department of Pulmonary and Critical Care Medicine, Qilu Hospital of Shandong University
- Alberto Fumagalli
- Department of Medicine and Oncology, Moriggia-Pelascini Hospital, Gravedona ed Uniti
- Ming Lu
- Clinical Research Center of Shandong University
- Giuseppe Valmadre
- Department of Medicine and Oncology, Moriggia-Pelascini Hospital, Gravedona ed Uniti
- Jie Wei
- Department of Emergency Medicine, Renmin Hospital of Wuhan University
- Yuan Bian
- Department of Emergency Medicine, Shandong Provincial Clinical Research Center for Emergency and Critical Care Medicine, Institute of Emergency and Critical Care Medicine of Shandong University, Qilu Hospital of Shandong University
- Margherita Canesi
- Department of Neurological Rehabilitation, Moriggia-Pelascini Hospital, Gravedona ed Uniti
- Giovanni Damiani
- Department of Radiology, Moriggia-Pelascini Hospital, Gravedona ed Uniti
- Yuan Zhang
- Clinical Research Center of Shandong University
- Dexin Yu
- Department of Radiology, Qilu Hospital of Shandong University
- Jun Chen
- Department of Radiology, Renmin Hospital of Wuhan University
- Xiang Ji
- Department of Pulmonary and Critical Care Medicine, Qilu Hospital of Shandong University
- Wenhai Sui
- Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education, Chinese National Health Commission and Chinese Academy of Medical Sciences, The State and Shandong Province Joint Key Laboratory of Translational Cardiovascular Medicine
- Bailu Wang
- Clinical Research Center of Shandong University
- Shuo Wu
- Department of Emergency Medicine, Shandong Provincial Clinical Research Center for Emergency and Critical Care Medicine, Institute of Emergency and Critical Care Medicine of Shandong University, Qilu Hospital of Shandong University
- Attila Kovacs
- Department of Intensive Care Unit, Moriggia-Pelascini Hospital, Gravedona ed Uniti
- Miriam Revera
- Department of Cardiology, Moriggia-Pelascini Hospital, Gravedona ed Uniti
- Hao Wang
- Department of Critical Care Medicine, Qilu Hospital of Shandong University
- Xu Jing
- Department of Emergency Medicine, Shandong Provincial Clinical Research Center for Emergency and Critical Care Medicine, Institute of Emergency and Critical Care Medicine of Shandong University, Qilu Hospital of Shandong University
- Ying Zhang
- Department of Emergency Medicine, Shandong Provincial Clinical Research Center for Emergency and Critical Care Medicine, Institute of Emergency and Critical Care Medicine of Shandong University, Qilu Hospital of Shandong University
- Yuguo Chen
- Department of Emergency Medicine, Shandong Provincial Clinical Research Center for Emergency and Critical Care Medicine, Institute of Emergency and Critical Care Medicine of Shandong University, Qilu Hospital of Shandong University
- Yihai Cao
- Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet
- DOI
- https://doi.org/10.1038/s41467-021-21085-8
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 10
Abstract
In this single-arm clinical trial, the authors show that treatment of COVID-19 patients with bevacizumab, an anti-vascular endothelial growth factor drug, can improve PaO2/FiO2 ratios and oxygen-support status. Relative to an external control group, bevacizumab shows clinical efficacy by improving oxygenation.
